Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for HIV-associated inflammation
NCT02256592Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of fecal microbiome transplant in human immunodeficiency virus infection (HIV), sponsored by University of California, San Francisco. Primary endpoints: Safety of FMT at 24 weeks and Engraftment of donor microbiome at 8 weeks. Started Oct 2014; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02256592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256592.